Review Article

Biomarkers of Non Alcoholic Steatohepatitis: a systematic review and meta-analysis

Azra Izanloo, Kamran Ghaffarzadehgan , Seyed Majid Sadrzadeh, Zahra Behrooznia, Seyed Saleh Tabatabaie

Azra Izanloo
Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad,Iran

Kamran Ghaffarzadehgan
Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran. Email: kghafar46@gmail.com

Seyed Majid Sadrzadeh
Hasheminejad Hospital. Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Zahra Behrooznia
Student Research Committee, Faculty of Medicine, Mashhad Islamic Azad University, Mashhad, Iran

Seyed Saleh Tabatabaie
ENT-HNS Research Center, HazratRasoolAkram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Online First: April 03, 2019 | Cite this Article
Izanloo, A., Ghaffarzadehgan, K., Sadrzadeh, S., Behrooznia, Z., Tabatabaie, S. 2019. Biomarkers of Non Alcoholic Steatohepatitis: a systematic review and meta-analysis. The Cancer Press 5(1, 2, 3, 4): 15-25. DOI:10.15562/tcp.73


Introduction: NAFLD is a common cause of chronic liver disease worldwide. Progression of chronic liver disease leads to liver transplant, so theearly detection of the primary stages is of utmost importance. This study aims to perform a systematic review of pertinent literature to determine early stages of NASH and explorediagnostic biomarkers of ck-18 family.

Method: This study is systematic and Meta analysis. We searched articles of different levels published in pub med, Cochrane collaboration library until December 9, 2016. Two independent reviewers assessed articles according to predefined criteria and extracted relevant data. AUC and values related to each biomarker in NASH, NO NAFLD and NAFLD groups were analyzed.

Results:The total population of five studies incorporated in the meta-analysis consisted of 345 subjects with an average age of 69.45 ± 8.40 years. The AUC related to M30 for diagnosis of NASH was reported between 0.60 and 0.88, which was suitable to differentiate NASH from simple steatohepatotitis.

Conclusion: The results showed that M30 was a suitable biomarker for the diagnosis of NASH. It is considering that the use of biomarkers can reduce the need for biopsy for the diagnosis of NASH and consequently decreaserelated costs and risks.

References

Rafiq N, Younossi ZM. Evaluation and management of non-alcoholic fatty liver disease. Clin Liver Dis. 2009;13:249–66. DOI:10.1016/j.cld.2009.02.009. PubMed: PMID:19442917.

Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010; 28:155–161. DOI:10.1159/000282080. Pub Med PMID:20460905

Arun J. Sanyal, MBBS, MD1, Scott L. Friedman, MD2, Arthur J. McCullough, MD3, and Lara Dimick. challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an american association for the study of liver diseases (aasld) - food and drug administration (fda) joint workshop. Hepatology. 2015 April ; 61(4): 1392–1405. doi: [10.1002/hep.27678] Pub Med PMID: 25557690

Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129:113–121. Pub Med PMID:16012941

Younossi ZM, Gramlich T, Liu Y, et al. Non- alcoholic fatty liver:assessment of variability in the pathologic interpretations. Mod Pathol. 1998;11(6):560–5 .Pub Med PMID:9647594

Matteoni C, Younossi ZM, Gramlich T, et al. A non-alcoholic fatty liver disease: a spectrum of clinical and pathologic severity.Gastroenterology. 1999;116:1413–9. DOI: https://doi.org/10.1016/S0016-5085(99)70506-8

Rosenberg WM, Voelker M, Thiel R, European Liver Fibrosis Group, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127(6):1704–13. PubMed PMID:15578508

Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers.Hepatology. 2009;47(2):455–60. DOI:10.1002/hep.21984 pubMed PMID:18038452

Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology.2003;38(2):518–26. DOI: 10.1053/jhep.2003.50346 Pub Med PMID:12883497

Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD J Hepatol. 2009;50:165–73. DOI:10.1016/j.jhep.2008.07.035 PubMed PMID:18977552

Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18(11):1430–7. DOI:10.1007/s11695-008-9506-y PubMed PMID:18500507

Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27–33. DOI:10.1002/hep.21223 Pub Med PMID:16799979

Baranova A, Younossi ZM. The future is around the corner: non-invasive diagnosis of the progressive nonalcoholic steatohepatitis.Hepatology. 2008;47(2):373–5. DOI:10.1002/hep.22140 Pub Med PMID:18220279

Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with non-alcoholic fatty liver disease. Clin Gastro Hepatol 2009;7(11):1224–9. DOI:10.1016/j.cgh.2009.06.007 Pub Med PMID:19559819

Bondini S, Kleiner DE, Goodman Z, et al. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis. 2007;11:17–23. DOI:10.1016/j.cld.2007.02.002 Pub Med PMID:17544969

Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906. Pub Med PMID:15940625

Miele L, Forgione A, Gasbarrini G, et al. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114–25. DOI: 10.1016/j.trsl.2006.11.011 Pub Med PMID:17320797

Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and Nash Test) in patients with hyperlipidaemia. Aliment Pharmacol Ther.2007;25:207–18. DOI:10.1111/j.1365-2036.2006.03182.x PMID:17229244

Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27–33. DOI: 10.1002/hep.21223 Pub Med PMID:16799979

Chitturi S, Farell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21(1):27–41. Pub Med PMID:11296694

Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clinics in Liver Disease. 2007;11(1):75–104. DOI: 10.1016/j.cld.2007.02.011 Pub Med PMID:17544973

London R, George J. Pathogenesis of NASH: animal models. Clin Liver Dis. 2007;11(1):55–74. DOI:10.1016/j.cld.2007.02.010 Pub Med PMID:17544972

Zobair M. Younossi& Sandra Page &NilaRafiq&AybikeBirerdinc& Maria Stepanova& Noreen Hossain & Arian Afendy& Zahra Younoszai& Zachary Goodman &AnchaBaranova. A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis. OBES SURG 2011; 21:431–439. DOI:10.1007/s11695-010-0204-1 Pub Med PMID:20532833

Higgins, J.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011.

Zobair M. Younossi& Mohammed Jarrar& Clare Nugent &Manpreet Randhawa & Mariam Afendy& Maria Stepanova&NilaRafiq& Zachary Goodman &VikasChandhoke&Ancha Baranova. A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH). OBES SURG 2008; 18:1430–1437. DOI:10.1007/s11695-008-9506-y PMID:18500507

L. Diab D, Yerian L, Schauer P, R. Kashyap S, Lopez R, L. Hazen S, E. Feldstein A. Cytokeratin 18 Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients. ClinGastroenterolHepatol 2008 November ; 6(11): 1249–1254. doi: [10.1016/j.cgh.2008.07.016] Pub Med PMID: 18995215

Yilmaz Y, ErenF. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. ClinicaChimicaActa 2012; 414: 154–157. DOI:10.1016/j.cca.2012.08.005 pub Med PMID:22985537

Kamada Y, Akita M, Takeda Y, Yamada S, Fujii H, Sawai Y, Doi Y. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS One. 2013 Jun 21;8(6):e66328. DOI:10.1371/journal.pone.0066328 PubMed PMID:23805214

Blomme B, Francque S, Trépo E, Libbrecht L, Vanderschaeghe D, Verrijken A, Pattyn P, Nieuwenhove YV, Putte DV, Geerts A, Colle I, Delanghe J, Moreno C, Gaal LV, Callewaert N, Vlierberghe HV. N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. Dig Liver Dis. 2012 Apr;44(4):315-22. DOI:10.1016/j.dld.2011.10.015 PMID:22119618

Corey KE, Lai M, Gelrud LG, Misdraji J, Barlow LL, Zheng H, Andersson KL, Thiim M, Pratt DS, Chung RT. Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. ClinGastroenterolHepatol. 2012 Jun;10(6):651-6. DOI:10.1016/j.cgh.2012.01.017 PMID:22330232

Imajo K, Fujita K, Yoneda M, Shinohara Y, Suzuki K, Mawatari H, Takahashi J, et al. Plasma free choline is a novel non-invasive biomarker for early-stage non-alcoholic steatohepatitis: A multi-center validation study Hepatology Research 2012; 42: 757–766. DOI:10.1111/j.1872-034X.2012.00976.x Pub Med PMID:22780848

Yoneda M, Nozaki Y, Endo H, Mawatari H, Iida H, Fujita K, Yoneda K, Takahashi H, Kirikoshi H, Inamori M, Kobayashi N, Kubota K, Saito S, Maeyama S, Hotta K, Nakajima A. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci. 2010 Mar;55(3):808-14. DOI:10.1007/s10620-009-0771-y Pub Med PMID:19267193

E. Feldstein A , Wieckowska A, Lopez R, Liu Y-Ch, N. Zein N, J. McCullough A. Cytokeratin-18 fragment levels as noninvasive biomarker for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology. 2009 Oct; 50(4): 1072–1078. DOI:10.1002/hep.23050 pub Med PMID:19585618

Younossi ZM, Gorreta F, Ong JP, Schlauch K, Giacco LD, Elariny H, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005;25:760–71. DOI:10.1111/j.1478-3231.2005.01117.x Pub Med PMID:15998427

Ramalho RM, Cortez-Pinto H, Castro RE, Sola S, Costa A, Moura MC, et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J GastroenterolHepatol. 2006; 18:21–9. Pub Med PMID:16357615

Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004;99:1708–17. DOI:10.1111/j.1572-0241.2004.40009.x PubMed PMID:15330907

Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. HEPATOLOGY 2012; 55:455-464. DOI:10.1002/hep.24734 Pub Med PMID:21993925

Choi S, Diehl AM. After Goodbye? Dead Hepatocytes as a Biomarker for Fibrosis and Steatohepatitis. Hepatology. 2012 Feb;55(2):333-5. DOI:10.1002/hep.25540 PMID:22183709

Baranova A, Younossi ZM. Adipokines in non-alcoholic fatty liver diseases. In: Fantuzzi G, Mazzone T, editors. Adipose tissue and adipokines in health and disease. New York: Humana Press; 2007. p. 291–307.


No Supplementary Material available for this article.
Article Views      : 304
PDF Downloads : 120